Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target Raised to $3.00

Ironwood Pharmaceuticals (NASDAQ:IRWD) had its target price raised by Wells Fargo & Company from $1.00 to $3.00 in a research report sent to investors on Tuesday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the biotechnology company’s stock.

Other equities research analysts have also issued research reports about the company. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Zacks Research downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $5.34.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD opened at $3.37 on Tuesday. The business’s 50-day moving average is $1.62 and its two-hundred day moving average is $1.10. The company has a market capitalization of $547.40 million, a P/E ratio of -67.39 and a beta of 0.37. Ironwood Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $5.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.15. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The business had revenue of $122.06 million during the quarter, compared to analysts’ expectations of $74.22 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts forecast that Ironwood Pharmaceuticals will post 0.1 EPS for the current year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in IRWD. Merit Financial Group LLC raised its holdings in Ironwood Pharmaceuticals by 17.4% in the third quarter. Merit Financial Group LLC now owns 48,879 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 7,232 shares in the last quarter. Rhumbline Advisers increased its position in shares of Ironwood Pharmaceuticals by 3.5% in the 3rd quarter. Rhumbline Advisers now owns 223,229 shares of the biotechnology company’s stock valued at $292,000 after purchasing an additional 7,611 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Ironwood Pharmaceuticals by 83.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 34,331 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 15,594 shares during the last quarter. State of Wyoming raised its holdings in shares of Ironwood Pharmaceuticals by 40.4% in the 1st quarter. State of Wyoming now owns 58,775 shares of the biotechnology company’s stock valued at $86,000 after purchasing an additional 16,917 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC lifted its position in shares of Ironwood Pharmaceuticals by 43.5% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 72,706 shares of the biotechnology company’s stock worth $95,000 after purchasing an additional 22,029 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.